Edition:
United States

Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

20.85USD
4:00pm EDT
Change (% chg)

$0.10 (+0.48%)
Prev Close
$20.75
Open
$20.80
Day's High
$20.95
Day's Low
$20.55
Volume
152,791
Avg. Vol
435,647
52-wk High
$21.83
52-wk Low
$3.20

Chart for

About

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of... (more)

Overall

Beta: 1.49
Market Cap(Mil.): $1,239.76
Shares Outstanding(Mil.): 59.75
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.15 16.18
EPS (TTM): -- -- --
ROI: -- 3.01 14.60
ROE: -- 4.76 13.87

BRIEF-Dynavax Technologies says ‍on August 21 court entered an order preliminarily approving a proposed settlement​

* Dynavax Technologies Corp says ‍on August 21 court entered an order preliminarily approving a proposed settlement​

Sep 01 2017

BRIEF-Vectura says global development agreement with Dynavax

* VECTURA'S AKITA SMART NEBULISER TO BE USED BY DYNAVAX TO DELIVER DV281

Aug 16 2017

BRIEF-Dynavax announces exercise in full of over-allotment option

* Dynavax announces exercise in full of over-allotment option and completion of public offering of common stock Source text for Eikon: Further company coverage:

Aug 15 2017

BRIEF-Dynavax announces proposed public offering of common stock

* Dynavax Technologies Corp - ‍intends to offer and sell $125.0 million of shares of its common stock​

Aug 08 2017

BRIEF-Dynavax provides U.S. regulatory update on heplisav-b following FDA advisory committee meeting

* Dynavax provides U.S. regulatory update on heplisav-b(tm) following fda advisory committee meeting

Aug 03 2017

BRIEF-Dynavax reports Q2 loss per share $0.41

* Q2 earnings per share view $-0.45 -- Thomson Reuters I/B/E/S

Aug 02 2017

Data supports safety of Dynavax hepatitis B vaccine: U.S. FDA panel

Available data supports the safety of Dynavax Technologies Corp's experimental hepatitis B vaccine when administered to adults, a panel of expert advisers to the U.S. Food and Drug Administration said on Friday.

Jul 28 2017

UPDATE 1-Data supports safety of Dynavax hepatitis B vaccine -U.S. FDA panel

July 28 Available data supports the safety of Dynavax Technologies Corp's experimental hepatitis B vaccine when administered to adults, a panel of expert advisers to the U.S. Food and Drug Administration said on Friday.

Jul 28 2017

BRIEF-Dynavax announces FDA advisory committee vote in favor of Heplisav-B

* Dynavax announces FDA advisory committee vote in favor of Heplisav-B (tm)

Jul 28 2017

Data supports safety of Dynavax hepatitis B vaccine -U.S. FDA panel

July 28 Available data supports the safety of Dynavax Technologies Corp's experimental hepatitis B vaccine when administered to adults, a panel of expert advisers to the U.S. Food and Drug Administration said on Friday.

Jul 28 2017

Competitors

Earnings vs. Estimates